PREOB®, Bone Therapeutics’ autologous osteoblastic cell therapy product, is derived from ex vivo cultured bone marrow cells of the patients. Phase II clinical results have already demonstrated excellent safety and efficacy results, with statistically and clinically relevant benefits, giving Bone Therapeutics a strong clinical rationale to continue clinical development. PREOB® is currently in two pivotal Phase III trials in Europe for osteonecrosis and non-union fractures. PREOB® received orphan drug designation for osteonecrosis from the EMA in October 2007 and from the FDA in March 2008.
Warning: PREOB® is an investigational product and is not yet available for sale. This website is not intended to provide medical advice or as a substitute for professional healthcare. Consult your doctor or medical provider for information about your diagnosis, treatment or condition.